RBC Capital reiterates IBM stock Outperform rating on AI security

RBC Capital reiterated an Outperform rating on IBM with a $300 price target, implying roughly 13% upside from the cited $265.34 share price. The article also highlights 7 upward earnings revisions, nearly 10% revenue growth, and a low PEG ratio of 0.24, while IBM secured a $46.24 million contract modification and will receive $1 billion in Chips Act funding for quantum computing. These developments support IBM’s AI, open-source software, and quantum strategy, though the news is more incremental than transformative.

Analysis

IBM is starting to look less like a cyclical legacy software rerating and more like a policy-backed infrastructure beneficiary with multiple embedded call options. The combination of federal cyber/defense work and quantum funding creates a more durable narrative than the market usually assigns to a mature large-cap tech name, because these revenue streams are sticky, procurement-driven, and less exposed to enterprise IT budget pauses. The second-order effect is that IBM can fund higher R&D intensity without the market penalizing near-term margin compression as long as the AI/security story keeps winning analyst revisions.

The more interesting angle is that the upside may be coming from perception lag rather than fundamental surprise. If the market starts treating IBM as a “strategic compute and security platform” instead of a slow-growth software company, multiple expansion could do more work than earnings growth over the next 6-12 months. That said, quantum-related capital allocation is a long-dated promise: the stock can rerate on policy headlines, but the actual cash flow inflection from quantum is likely years away, so any premium may be vulnerable if execution slips or the AI security initiative fails to show monetization.

Consensus seems to be underappreciating the asymmetry between near-term contracted revenue and long-term optionality. The bull case does not require IBM to win a broad AI platform war; it only needs to remain an enterprise trust layer while the market pays up for defensible infrastructure exposure. The risk is that investors overstate quantum as a near-term earnings lever and underweight the possibility that the stock becomes range-bound again once the headline cycle fades.

Key Decisions for Investors

• Go long IBM on pullbacks in the low-$260s with a 3-6 month target around the low-$290s; thesis is multiple expansion from strategic positioning, not just EPS growth. Risk/reward is roughly 1:3 if the market continues to reward policy-backed AI/security exposure.
• For a cleaner expression of the catalyst, buy IBM Jan-2026 calls or call spreads to capture rerating potential while limiting downside if quantum execution takes longer than expected.
• Pair trade: long IBM / short a basket of slower-growth legacy IT services names over the next 2-4 quarters; IBM has more credible policy-supported optionality and should absorb capital if investors rotate toward “secure AI infrastructure.”
• Trim or hedge if IBM fails to hold analyst-upgrade momentum over the next earnings cycle; the stock’s premium is vulnerable if revenue growth reverts toward low-single digits and the market decides quantum headlines are too far out.